Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues
ResearchMoz has recently added the "Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2013 Edition" report to its vast database of research reports.The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Orphan Drugs Market in Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope. But is this enough...
View full press release